Evaluation of the Abnormal Platelet Function in von Willebrand Disease by the Blood Filtration Test

Francesco I Pareti; Marco Cattaneo; Luca Carpinelli; Maddalena L Zighetti; Caterina Bressi; Pier Mannuccio Mannucci; Zaverio M Ruggeri

doi:10.1055/s-0038-1650600

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1996; 76(03): 460-468
DOI: 10.1055/s-0038-1650600

Original Article

Schattauer GmbH Stuttgart

Evaluation of the Abnormal Platelet Function in von Willebrand Disease by the Blood Filtration Test

Francesco I Pareti

¹The Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Institute of Internal Medicine, IRCCS Maggiore Hospital and University of Milan, Italy

,

Marco Cattaneo

¹The Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Institute of Internal Medicine, IRCCS Maggiore Hospital and University of Milan, Italy

,

Luca Carpinelli

¹The Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Institute of Internal Medicine, IRCCS Maggiore Hospital and University of Milan, Italy

,

Maddalena L Zighetti

¹The Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Institute of Internal Medicine, IRCCS Maggiore Hospital and University of Milan, Italy

,

Caterina Bressi

¹The Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Institute of Internal Medicine, IRCCS Maggiore Hospital and University of Milan, Italy

,

Pier Mannuccio Mannucci

¹The Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Institute of Internal Medicine, IRCCS Maggiore Hospital and University of Milan, Italy

,

Zaverio M Ruggeri

²The Roon Research Center for Arteriosclerosis and Thrombosis, Division of Experimental Hemostasis and Thrombosis, Departments of Molecular and Experimental Medicine and of Vascular Biology, The Scripps Research Institute, La Jolla, CA, USA

› Institutsangaben

Abstract

als PDF herunterladen

Summary

We have evaluated platelet function in different subtypes of von Willebrand disease (vWD) by pushing blood through the capillarysized channels of a glass filter. Patients, including those with type IIB vWD, showed lower than normal platelet retention and increased cumulative number of blood drops passing through the filter as a function of time. In contrast, shear-induced platelet aggregation, measured in the cone-and-plate viscometer, was paradoxically increased in type IIB patients. Treatment with l-desamino-8-D-arginine vasopressin (DDAVP) tended to normalize the filter test in patients with type I-platelet normal and type I-platelet low vWD, but infusion of a factor VUI/von Willebrand factor (vWF) concentrate lacking the largest vWF multimers was without effect in type 3 patients. Experiments with specific monoclonal antibodies demonstrated that the A1 and A3 domains of vWF, as well as the glycoproteins Ibα and Ilb-IIIa on platelets, are required for platelet retention in the filter. Thus, the test may reflect vWF function with regard to both platelet adhesion and aggregation under high shear stress, and provide relevant information on mechanisms involved in primary hemostasis.

PDF (481 kb)

Referenzen

References
1 Weiss HJ, Turitto VT, Baumgartner HR. Effect of shear rate on platelet interaction with subendothelium in citrated and native blood. I. Shear rate-dependent decrease of adhesion in von Willebrand’s disease and the Bemard-Soulier syndrome. J Lab Clin Med 1978; 92: 750-764
2 Ruggeri ZM. The Platelet Glycoprotein Ib-IX Complex. In: Progress in Hemostasis and Thrombosis Coller BS. ed. W. B. Saunders Company; Philadelphia, PA: 1991: 35-68
3 Savage B, Shattil SJ, Ruggeri ZM. Modulation of platelet function through adhesion receptors: A dual role for glycoprotein Ilb-IIIa (integrin α_IIbβ₃) mediated by fibrinogen and glycoprotein Ib-von Willebrand factor. J Biol Chem 1992; 267: 11300-11306
4 Savage B, Saldivar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand Factor. Cell 1996; 84: 289-297
5 Chow TW, Heliums JD, Moake JL, Kroll MH. Shear stress-induced von Willebrand factor binding to platelet glycoprotein lb initiates calcium influx associated with aggregation. Blood 1992; 80: 113-120
6 Ikeda Y, Handa M, Kamata T, Kawano K, Kawai Y, Watanabe K, Sakai K, Mayumi F, Itagaki I, Yoshioka A, Ruggeri ZM. Transmembrane calcium influx associated with von Willebrand factor binding to GP lb in the initiation of shear-induced platelet aggregation. Thromb Haemost 1993; 69: 496-502
7 Goto S, Salomon DR, Ikeda Y, Ruggeri ZM. Characterization of the unique mechanism mediating the shear-dependent binding of soluble von Willebrand factor to platelets. J Biol Chem 1995; 270: 23352-23361
8 Giorgio TD, Heliums JD. A cone and plate viscometer for the continuous measurement of blood platelet activation. Biorheology 1988; 25: 605-624
9 Fukuyama M, Sakai K, Itagaki I, Kawano K, Murata M, Kawai Y, Watanabe K, Handa M, Ikeda Y. Continuous measurement of shear-induced platelet aggregation. Thromb Res 1989; 54: 253-260
10 Moake JL, Turner NA, Stathopoulos NA, Nolasco LH, Heliums JD. Involvement or large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest 1986; 78: 1456-1461
11 Baumgartner HR. The role of blood flow in platelet adhesion, fibrin deposition and formation of mural thrombi. Microvasc Res 1973; 5: 167-179
12 Sakariassen KS, Bolhuis PA, Sixma JJ. Human blood platelet adhesion to artery subendothelium is mediated by factor VUI/von Willebrand factor bound to the subendothelium. Nature 1979; 279: 636-638
13 Ikeda Y, Handa M, Kawano K, Kamata T, Murata M, Araki Y, Anbo H, Kawai Y, Watanabe K, Itagaki I, Sakai K, Ruggeri ZM. The role of von Willebrand Factor and fibrinogen in platelet aggregation under varying shear stress. J Clin Invest 1991; 87: 1234-1240
14 Alevriadou BR, Moake JL, Turner NA, Ruggeri ZM, Folie BJ, Phillips MD, Schreiber AB, Hrinda ME, Mclntire LV. Real-time analysis of shear-dependent thrombus formation and its blockade by inhibitors of von Willebrand factor binding to platelets. Blood 1993; 81: 1263-1276
15 Turitto VT, Weiss HJ, Baumgartner HR. Platelet interaction with rabbit subendothelium in von Willebrand’s disease: altered thrombus formation distinct from defective platelet adhesion. J Clin Invest 1984; 74: 1730-1741
16 Sakariassen KS, Cattaneo v. d. M, Berg A, Ruggeri ZM, Mannucci PM, Sixma JJ. DDAVP enhances platelet adherence and platelet aggregate growth on human artery subendothelium. Blood 1984; 64: 229-236
17 Ruggeri ZM, Pareti FI, Mannucci PM, Ciavarella N, Zimmerman TS. Heightened interaction between platelets and Factor VIII/Von Willebrand factor in a new subtype of von Willebrand’s disease. N Engl J Med 1980; 302: 1047-1051
18 Ruggeri ZM, Zimmerman TS. Variant von Willebrand’s disease: characterization of two subtypes by analysis of multimeric composition of factor VUI/von Willebrand factor in plasma and platelets. J Clin Invest 1980; 65: 1318-1325
19 De Marco L, Girolami A, Zimmerman TS, Ruggeri ZM. Interaction of purified IIB von Willebrand factor with the platelet membrane glycoprotein lb induces fibrinogen binding to the glycoprotein IIb/IIIa complex and initiates aggregation. Proc Natl Acad Sci USA 1985; 82: 7424-7428
20 De Marco L, Mazzuccato M, Del Ben MG, Budde U, Federici AB, Girolami A, Ruggeri ZM. Type IIB von Willebrand factor with normal sialic acid content induces platelet aggregation in the absence of ristocetin. Role of platelet activation, fibrinogen, and two distinct membrane receptors J Clin Invest 1987; 80: 475-482
21 Murata M, Fukuyama M, Satoh K, Fujimura Y, Yoshioka A, Takahashi H, Handa M, Kawai Y, Wanaabe K, Ikeda Y. Low shear stress can initiate von Willebrand factor-dependent platelet aggregation in patients with type IIB and platelet-type von Willebrand disease. J Clin Invest 1994; 92: 1555-1558
22 O’Brien JR, Salmon GP. Shear stress activation of platelet glycoprotein Ilb/IIIa plus von Willebrand factor causes aggregation: filter blockage and the long bleeding time in von Willebrand’s Disease. Blood 1987; 70: 1354-1361
23 Ruggeri ZM, Zimmerman TS. von Willebrand factor and von Willebrand disease. Blood 1987; 70: 895-904
24 Mannucci PM, Lombardi R, Bader R, Vianello L, Federici AB, Solinas S, Mazzucconi MG, Mariani G. Heterogeneity of type I von Willebrand disease: evidence for a subgroup with an abnormal von Willebrand factor. Blood 1985; 66: 796-802
25 Sadler JE. A revised classification of von Willebrand disease. For the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1994; 71: 520-525
26 Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A. l-Deamino-8-d-argi-nine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrand’s diseases. Lancet 1977; I: 869-872
27 Holmberg L, Nilsson IM, Borge L, Gunnarsson M, Sjorin E. Platelet aggregation induced by l-desamino-8-D-arginine vasopressin (DDAVP) in Type IIB von Willebrand’s disease. N Engl J Med 1983; 309: 816-821
28 Mannucci PM, Canciani MT, Rota L, Donovan BS. Response of factor VUI/von Willebrand factor to DDAVP in healthy subjects and patients with haemophilia A and von Willebrand’s disease. Br J Haematol 1981; 47: 283-293
29 Ruggeri ZM, Mannucci PM, Jeffcoate SL, Ingram GIC. Immunoradio-metric assay of Factor VIII related antigen, with observations in 32 patients with von Willebrand’s disease. Br J Haematol 1976; 33: 221-238
30 Ruggeri ZM, Mannucci PM, Bader R, Barbui T. Factor VIII-related properties in platelets from patients with von Willebrand’s disease. J Lab Clin Med 1978; 91: 132-140
31 Bamber M, Murray A, Kemoff PB, Thomas HC. Short incubation non-A, non-B hepatitis transmitted by factor VIII concentrates in patients with congenital coagulation disorders: a preliminary report of an antigen/antibody system. Med Lab Sci 1981; 38: 373-378
32 Ey PL, Prowse SJ, Jenkin CR. Isolation of pure IgGl, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-Sepharose. Immuno-chemistry 1978; 15: 429-436
33 Fujimura Y, Usami Y, Titani K, Niinomi K, Nishio K, Takase T, Yoshioka A, Fukui H. Studies on Anti-von Willebrand Factor (vWF) Monoclonal Antibody NMC-4, Which Inhibits Both Ristocetin- and Botrocetin-Induced vWF Binding to Platelet Glycoprotein lb. Blood 1991; 77: 113-120
34 Mohri H, Yoshioka A, Zimmerman TS, Ruggeri ZM. Isolation of the von Willebrand factor domain interacting with platelet glycoprotein lb, heparin, and collagen, and characterization of its three distinct functional sites. J Biol Chem 1989; 264: 17361-17367
35 Sugimoto M, Dent J, McClintock RS, Ware J, Ruggeri ZM. Analysis of structure-function relationship in the platelet membrane glycoprotein Ib-binding domain of von Willebrand’s factor by expression of deletion mutants. J Biol Chem 1993; 268: 12185-12192
36 Shelton-Inloes BB, Titani K, Sadler JE. cDNA sequences for human von Willebrand factor reveal five types of repeated domains and five possible protein sequence polymorphisms. Biochemistry 1986; 25: 3164-3171
37 Roth GJ, Titani K, Hoyer LW, Hickey MJ. Localization of binding sites within human von Willebrand factor for monomeric Type III collagen. Biochemistry 1986; 25: 8357-8361
38 Ruggeri ZM, De Marco L, Gatti L, Bader R, Montgomery RR. Platelets have more than one binding site for von Willebrand factor. J Clin Invest 1983; 72: 1-12
39 Pareti FI, Niiya K, McPherson JM, Ruggeri ZM. Isolation and characterization of two domains of human von Willebrand factor that interact with fibrillar collagen Types I and III. J Biol Chem 1987; 262: 13835-13841
40 Girma J-P, Chopek MW, Titani K, Davie EW. Limited proteolysis of human vWF by staphylococcus aureus V-8 protease: isolation and partial characterization of a platelet-binding domain. Biochemistry 1986; 25: 3156-3163
41 Niiay K, Hodson E, Bader R, Byers-Ward V, Koziol JA, Plow EF, Ruggeri ZM. Increased surface expression of the membrane glycoprotein Ilb/IIIa complex induced by platelet activation. Relationship to the binding of fibrinogen and platelet aggregation. Blood 1987; 70: 475-483
42 Sugimoto M, Ricca G, Hrinda ME, Schreiber AB, Searfoss GH, Bottini E, Ruggeri ZM. Functional modulation of the isolated glycoprotein Ib-binding domain of von Willebrand factor expressed in Escherichia coli. Biochemistry 1991; 30: 5202-5209
43 Peterson DM, Stathopoulos NA, Giorgio TD, Heliums JD, Moake JL. Shear-induced platelet aggregation requires von Willebrand factor and platelet membrane glycoproteins Ib and IIb-IIIa. Blood 1987; 69: 625-628
44 Belval TK, Heliums JD, Solis RT. The kinetics of platelet aggregation induced by fluid-shearing stress. Microvas Res 1984; 28: 279-288
45 Ware J, Dent JA, Azuma H, Sugimoto M, Kyrle PA, Yoshioka A, Ruggeri ZM. Identification of a point mutation in Type IIB von Willebrand disease illustrating the regulation of von Willebrand factor affinity for the platelet GP Ib-IX receptor. Proc Natl Acad Sci USA 1991; 88: 2946-2950
46 Ginsburg D, Sadler JE. von Willebrand Disease: A Database of point mutations, insertions and deletions. Thromb Haemost 1993; 69: 177-184
47 De Marco L, Mazzucato M, De Roia D, Casonato A, Federici AB, Girolami A, Ruggeri ZM. Distinct abnormalities in the interaction of purified IIA and IIB von Willebrand factor with the two platelet binding sites GP Ib-IX and GP Ilb-IIIa. J Clin Invest 1990; 86: 785-792
48 Gralnick HR, Rick ME, McKeown LP, Williams SB, Parker RI, Maison-neuve P, Jenneau C, Sultan Y. Platelet von Willebrand factor: an important determinant of the bleeding time in type I von Willebrand disease. Blood 1986; 68: 58-61